Arterys and Whiterabbit.ai are collaborating in an AI-driven partnership to significantly increase breast cancer compliance. The program is designed to increase mammography screening compliance and volume and aid in early breast cancer detection. It also has the potential to reduce the backlog of missed preventive screenings that remain overdue due to the COVID-19 pandemic.
Whiterabbit.ai is an AI-technology company that targets late-stage diseases by providing more accurate and early cancer detection. Among their powerful solutions is their ACT AI-powered software purpose-built to dramatically increase breast cancer screening compliance. They achieve this by analyzing millions of data points and employing a personalized notification system that motivates women to comply with mammography recommendations.
The ACT system has been tested in more than 300 U.S. breast cancer screening centers with more than a 20% growth year-over-year. Their solution helps save lives and eliminates the need for costly one-on-one follow ups.
The program is designed to increase mammography screening compliance and volume and early detection of breast cancer. This union furthers Whiterabbit's mission to combat late-stage diseases through increased accessibility and integration of AI-powered healthcare software.
As Whiterabbit's CEO Alexander Sardiña, MD notes:
“We believe AI has the power to transform healthcare through compliance and across the care continuum. Whiterabbit is dedicated to research and development of products in partnership with leading institutions and organizations that improve the accuracy and efficiency of detection and diagnosis and patient care, while reducing costs.”
And we couldn't agree more.
Dan Arnoff, Arterys' Senior VP of Commercialization elaborates:
“ACT drives the compliance of screening mammograms which in turn reduces interval cancers. ACT combined with our current Breast AI solution for tomosynthesis provides the end user a very unique platform in the fight against breast cancer. Arterys is committed to developing the best of class AI solutions, deployed from a single cloud interface to maximize the power of AI to Breast Centers across the globe.”
Through the partnership, clinics and hospitals already using Arterys' Breast AI platform to detect breast cancer, measure breast density, and deliver risk assessments can purchase and integrate ACT into their compliance programs. This successfully increases the number of women who schedule annual mammograms.
To learn more about our exciting partnership with Whiterabbit.ai, please read the full press release.
Arterys: May 02, 2023
Arterys, a Tempus company, has announced a US and EU distribution agreement with Therapixel, a medical imaging software company providing AI...
Arterys: Apr 19, 2023
The 2023 Society of Breast Imaging (SBI) Breast Imaging Symposium is a must-attend event for radiologists and healthcare professionals involved in...
Arterys: Feb 27, 2023
There are a lot of radiology conferences and events in March, and you can connect with the Arterys team at a number of them! Six specific events in...
Arterys